Sort
25,944 grants matching “neurodegeneration”
Exploring mechanisms of Parkinson's disease-linked D620N VPS35 in rat models
$446,500Darren John Moore · Van Andel Research Institute · R01 · FY2020 · NS
Epigenetic contributions to symptom asymmetry in Parkinson's disease
$446,500Gerhard A Coetzee · Van Andel Research Institute · R01 · FY2023 · NS
Exploring mechanisms of Parkinson's disease-linked D620N VPS35 in rat models
$446,500Darren John Moore · Van Andel Research Institute · R01 · FY2021 · NS
AAV Gene Therapy for the CNS in MPS VII
$446,473John H Wolfe · Children'S Hosp Of Philadelphia · R01 · FY2008 · NS
Genetic Control of Programmed Cell Death in Drosphila
$446,448Andreas Bergmann · Univ Of Massachusetts Med Sch Worcester · R01 · FY2013 · GM
Cannabidiol and Older Adult Cannabis Users: A Randomized, Placebo Controlled Study
$446,278Angela D Bryan · University Of Colorado Denver · P50 · FY2025 · DA
Cannabidiol and Older Adult Cannabis Users: A Randomized, Placebo Controlled Study
$446,278Angela D Bryan · University Of Colorado Denver · P50 · FY2024 · DA
Pathological role of c-Abl in alpha-synucleinoapathy
$446,132Michael K Lee · University Of Minnesota · R01 · FY2018 · NS
iPSC-derived Neurovascular Organoids
$446,111Ethan Lippmann · Vanderbilt University · R01 · FY2020 · NS
Genetic basis of chemotherapy-induced neuropathy in a reduced complexity cross
$446,100Mohamad Imad Damaj · Virginia Commonwealth University · R01 · FY2020 · CA
Ifi27l2a as a therapeutic target for stroke
$446,035Gab Seok Kim · University Of Texas Hlth Sci Ctr Houston · R01 · FY2024 · NS
The Nrf2-ARE pathway in modulating Parkinson's Disease
$445,999Jeffrey A Johnson · University Of Wisconsin-Madison · R01 · FY2006 · ES
J147 Treatment for Traumatic Brain Injury in Brain Damage and Long-Term Functional Recovery
$445,995Rong Jin · Pennsylvania State Univ Hershey Med Ctr · R21 · FY2021 · NS
Spastic paraplegia, neurodegeneration and autism: possible role for AT- 1/SLC33A1?
$445,993Luigi Puglielli · University Of Wisconsin-Madison · R01 · FY2022 · NS
Spastic paraplegia, neurodegeneration and autism: possible role for AT- 1/SLC33A1?
$445,993Luigi Puglielli · University Of Wisconsin-Madison · R01 · FY2023 · NS
The Nrf2-ARE pathway in modulating Parkinson's Disease
$445,975Jeffrey A Johnson · University Of Wisconsin-Madison · R01 · FY2009 · ES
Defining immune cell heterogeneity in human ALS and mouse model of the disease
$445,897Serge E Przedborski · Columbia University Health Sciences · R01 · FY2022 · NS
Defining Immune Cell Heterogeneity in Human ALS and Mouse Model of the Disease
$445,897Serge E Przedborski · Columbia University Health Sciences · R01 · FY2023 · NS
Mechanisms of Polyglutamine Neurodegeneration
$445,776Henry L Paulson · University Of Michigan At Ann Arbor · R01 · FY2013 · NS
Nanoparticle-mediated reduction of oxidative stress for the treatment of traumatic brain injury
$445,684Forrest M Kievit · University Of Nebraska Lincoln · R01 · FY2020 · NS
Nanotechnology for Glial Targeting and Inhibition of Neuroinflammation for Alzheimerâs Disease
$445,625Prabhas V Moghe · Rutgers, The State Univ Of N.J. · R21 · FY2024 · AG
Cell Signaling and Neurodegeneration
$445,610Harry T. Orr · University Of Minnesota · R01 · FY2014 · NS
Histone Deacetylation Signaling in Aging and Cancer Pathways
$445,595Katrin F Chua · Palo Alto Veterans Instit For Research · R01 · FY2022 · CA
Identifying shared and distinct cell type vulnerability across neurological diseases.
$445,500Vilas Menon · Columbia University Health Sciences · R21 · FY2022 · AG
Focused ultrasound and synucleinopathy
$445,500Serge E Przedborski · Columbia University Health Sciences · R21 · FY2019 · NS